Regencell (RGC) Completes 38-for-1 Stock Split

Regencell Bioscience Holdings Limited (NASDAQ:RGC) is one of the 12 Best Performing Stocks in the Last 6 Months. On June 17, Regencell Bioscience Holdings Limited (NASDAQ:RGC) announced that it had carried out a 38-for-1 forward stock split.

For every share held on the record date, investors received 37 additional shares as a stock bonus. This stock split was announced on June 2.

Regencell Bioscience Holdings Limited (NASDAQ:RGC) pointed out that this stock split is aimed at improving liquidity in the market for the company’s ordinary shares and making the shares more accessible to investors.

In the past 6 months, Regencell Bioscience Holdings Limited (NASDAQ:RGC) has gone up dramatically, surging by more than 13,000% as of July 29.

The rally can be attributed in part to the completion of the stock split by Regencell Bioscience Holdings Limited (NASDAQ:RGC), which helped push the stock price higher.

Regencell Bioscience Holdings Limited (NASDAQ:RGC) is a Hong Kong-based bioscience company focused on researching, developing, and commercializing traditional Chinese medicine (TCM) for the treatment of attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD).

While we acknowledge the potential of RGC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.